Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-09-24 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于股东部分股份解除冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the unfreezing of a portion of shares held by a shareholder (魏学宁) in the company 长春百克生物科技股份公司. It details the number of shares unfrozen, the shareholder's total holdings, and the impact on company control. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The document is a regulatory announcement about share status changes related to a shareholder's holdings, specifically about the lifting of judicial freeze on shares. This fits best under the category of Major Shareholding Notification (MRQ), as it involves changes in significant share ownership status and related disclosures. The document length is short and focused on this specific shareholder event, not a full report or financial statement.
2025-09-24 Chinese
长春百克生物科技股份公司关于选举第六届董事会职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a staff representative director to the company's sixth board of directors. It includes details about the election process, the elected individual's biography, and compliance with relevant laws and regulations. There is no financial data, audit information, or report content. The document is clearly about a change in the company's board composition, specifically the election of a director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on this announcement, not a full report or presentation.
2025-09-16 Chinese
长春百克生物科技股份公司2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 second extraordinary shareholders' meeting of Changchun Baike Biotechnology Co., Ltd. It includes details about the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholders' meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or a management report. The document is clearly an official declaration of voting results from a shareholders' meeting, which matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 1727 characters, which is consistent with a voting results announcement rather than a full report.
2025-09-16 Chinese
北京植德律师事务所关于长春百克生物科技股份公司2025年第二次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2025 second extraordinary shareholders' meeting. It details the meeting's convening, attendance, voting procedures, and results, confirming compliance with relevant laws and company bylaws. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an announcement of voting results but a legal opinion on the meeting's procedural aspects. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal procedural filing that does not fit other specific categories like Declaration of Voting Results (DVA) or Annual Report (10-K). The document length is 4109 characters, which is relatively short and focused on legal opinion rather than full report content.
2025-09-16 Chinese
长春百克生物科技股份公司2025年第二次临时股东会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2025 Second Extraordinary General Meeting of Shareholders" of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting instructions, agenda, and proposals for shareholder approval, including governance changes and amendments to company bylaws. The content is focused on the meeting process, shareholder rights, voting procedures, and specific agenda items to be discussed and voted on during the meeting. There are no financial statements or financial performance data included. The document is a set of meeting materials provided to shareholders for an extraordinary general meeting, which fits the definition of AGM Information (AGM-R). The document length is 4560 characters, which is consistent with a meeting material document rather than a brief announcement or a full report. Therefore, the classification is AGM Information (AGM-R).
2025-09-05 Chinese
长春百克生物科技股份公司关于2025年度提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度评估报告" (half-year evaluation report) for a specific action plan in 2025 by Changchun Baike Biotechnology Co., Ltd. It contains detailed operational, marketing, R&D, governance, and financial information for the half-year period. The content includes financial figures, progress on projects, governance updates, and shareholder return strategies, indicating a comprehensive interim report rather than a brief announcement or a simple regulatory filing. The length is over 6,500 characters, supporting it being a substantive report. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year with substantive financial data and analysis. H1 2025
2025-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.